WO1994020115A3 - Acide hyaluronique utilise comme traitement contre le cancer - Google Patents

Acide hyaluronique utilise comme traitement contre le cancer Download PDF

Info

Publication number
WO1994020115A3
WO1994020115A3 PCT/US1994/002506 US9402506W WO9420115A3 WO 1994020115 A3 WO1994020115 A3 WO 1994020115A3 US 9402506 W US9402506 W US 9402506W WO 9420115 A3 WO9420115 A3 WO 9420115A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
cancer treatment
acid used
preparations
tumor
Prior art date
Application number
PCT/US1994/002506
Other languages
English (en)
Other versions
WO1994020115A2 (fr
Inventor
Karen K Brown
Original Assignee
Miles Inc
Karen K Brown
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Miles Inc, Karen K Brown filed Critical Miles Inc
Priority to AU63625/94A priority Critical patent/AU6362594A/en
Publication of WO1994020115A2 publication Critical patent/WO1994020115A2/fr
Publication of WO1994020115A3 publication Critical patent/WO1994020115A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Préparations à base d'acide hyaluronique, qui soignent le cancer. Lesdites préparations peuvent contenir d'autres ingrédients tels que de l'acide lipotéichoïque et sont injectées de manière parentérale ou directement dans la tumeur. Toutes les préparations peuvent être utilisées de façon répétée sans effets secondaires toxiques.
PCT/US1994/002506 1993-03-10 1994-03-08 Acide hyaluronique utilise comme traitement contre le cancer WO1994020115A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63625/94A AU6362594A (en) 1993-03-10 1994-03-08 Hyaluronic acid used as a cancer treatment

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US2895793A 1993-03-10 1993-03-10
US08/028,957 1993-03-10

Publications (2)

Publication Number Publication Date
WO1994020115A2 WO1994020115A2 (fr) 1994-09-15
WO1994020115A3 true WO1994020115A3 (fr) 1994-11-10

Family

ID=21846439

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1994/002506 WO1994020115A2 (fr) 1993-03-10 1994-03-08 Acide hyaluronique utilise comme traitement contre le cancer

Country Status (2)

Country Link
AU (1) AU6362594A (fr)
WO (1) WO1994020115A2 (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5902795A (en) * 1992-06-16 1999-05-11 Trustees Of Tufts College Oligosaccharides reactive with hyaluronan-binding protein and their methods of use
CA2208780C (fr) * 1995-01-30 2010-03-30 Peter Truog Preparations antitumorales et anti-cholesterol comprenant un acide lipoteichoique, le lta-t, derive de streptococcus sp dsm 8747
JPH09163896A (ja) * 1995-12-13 1997-06-24 Sumitomo Pharmaceut Co Ltd 胸膜炎病態モデル動物
CA2175282A1 (fr) * 1996-04-29 1997-10-30 Rudolf Edgar Falk Utilisation de diverses formes d'acide hyaluronique (ah) pour le traitement du cancer
NZ520312A (en) 1999-12-28 2003-08-29 Bioniche Life Sciences Inc Hyaluronic acid in the treatment of cancer
EP1260227A1 (fr) 2001-05-23 2002-11-27 Societe Des Produits Nestle S.A. L'acide lipoteichoique des bacteries lactiques et son utilisation pour moduler des responses immunitaites induites par des bacteries a gram negatif, gram positif
CA2664158C (fr) * 2006-09-22 2015-11-24 Kochi University Sensibilisateur de rayonnement ou sensibilisateur de chimiotherapie anti-cancer

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135820A2 (fr) * 1983-08-26 1985-04-03 Chugai Seiyaku Kabushiki Kaisha Agent antitumoral
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
EP0208623A2 (fr) * 1985-07-12 1987-01-14 Sanofi Utilisation de poly- et oligosaccharides pour l'obtention de médicaments actifs dans les pathologies du tissu conjonctif
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
WO1989005646A1 (fr) * 1987-12-21 1989-06-29 Bukh Meditec A/S Utilisations de sucres sulfates
JPH01290631A (ja) * 1988-05-18 1989-11-22 Seikagaku Kogyo Co Ltd 血管内皮細胞増殖抑制剤

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0135820A2 (fr) * 1983-08-26 1985-04-03 Chugai Seiyaku Kabushiki Kaisha Agent antitumoral
US4678773A (en) * 1983-08-26 1987-07-07 Chugai Seiyaku Kabushiki Kaisha Antitumor agent
JPS6117A (ja) * 1984-06-11 1986-01-06 Seikagaku Kogyo Co Ltd ムコ多糖系癌転移抑制剤
US4725585A (en) * 1985-04-26 1988-02-16 Pharmacia Ab Method of enhancing the host defense
EP0208623A2 (fr) * 1985-07-12 1987-01-14 Sanofi Utilisation de poly- et oligosaccharides pour l'obtention de médicaments actifs dans les pathologies du tissu conjonctif
WO1989005646A1 (fr) * 1987-12-21 1989-06-29 Bukh Meditec A/S Utilisations de sucres sulfates
JPH01290631A (ja) * 1988-05-18 1989-11-22 Seikagaku Kogyo Co Ltd 血管内皮細胞増殖抑制剤

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Derwent World Patents Index; AN 90-011032 [02] *
PATENT ABSTRACTS OF JAPAN vol. 10, no. 139 (C - 348) *

Also Published As

Publication number Publication date
AU6362594A (en) 1994-09-26
WO1994020115A2 (fr) 1994-09-15

Similar Documents

Publication Publication Date Title
IE840378L (en) Detergent compositions
WO2000053730A3 (fr) TRAITEMENT DU DEFICIT EN α-GALACTOSIDASE
HU9602937D0 (en) Compositions comprising dna damaging agents and p53
AU6276194A (en) Use of monoterpenes, sesquiterpernes and diterpernes for the treatment of cancer
WO2002056912A3 (fr) Methode de traitement du cancer
GEP20043375B (en) APRIL-Receptor (BCMA) and Use Thereof
UA39158C2 (uk) Похідні n4-оксикарбоніл-5'-дезокси-5-фторцитидину та фармацевтичний препарат на їх основі
HK1030144A1 (en) Method for treatment of liver tumours and pharmaceutical compositions for use therein.
CA2170255A1 (fr) Composition pharmaceutique pour therapie par immunopotentialisation
AU3139097A (en) Methods of preventing skeletal problems in poultry
WO1996021468A3 (fr) Interferent chimiquement modifie
WO1998008505A8 (fr) Composes pharmaceutiques
PL308142A1 (en) Derivatives of 2-amino-4phenyl-4-oxobutyric acids as kynureninase and/or kynurenic 3-hydroxylase inhibitors
WO1997004788A3 (fr) Utilisation de glycosides de calendula dans le traitement du psoriasis
AU4896090A (en) Insecticide treatment and compositions therefor
WO1998009599A3 (fr) Utilisation d'un nouvel acide bicafeoylquinique dans le traitement de l'hepatite b et des maladies liees a des retrovirus, et derives de cet acide bicafeolyquinique
CA2120153A1 (fr) Immunotoxines recombinantes
IL107153A (en) Pharmaceutical compositions for preventing insulin-dependent diabetes mellitus comprising IL10 and method for their manufacture
WO1994020115A3 (fr) Acide hyaluronique utilise comme traitement contre le cancer
IL121272A (en) Pharmaceutical compositions comprising adenosine and their use for treating or preventing leukopenia
IL101410A0 (en) Formulation for the treatment of cancer
WO1998030585A3 (fr) Utilisation de pea3 en tant que suppresseur de tumeurs
EP0281070A3 (fr) Composé pharmaceutique pour le traitement du cancer
IL143516A0 (en) COMPOUNDS AND METHODS FOR MODULATING ACTIVATION OF NF-k-B
EP0744176A3 (fr) Médicaments pour inhiber les pertes osseuses

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

AK Designated states

Kind code of ref document: A3

Designated state(s): AT AU BB BG BR BY CA CH CN CZ DE DK ES FI GB GE HU JP KG KP KR KZ LK LU LV MD MG MN MW NL NO NZ PL PT RO RU SD SE SI SK TJ UA US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA